The integrins, widely expressed adhesive receptors, undergo conformational changes subsequent to ligand binding (1) . Recent reports document involvement of free sulfhydryls as well as disulfide exchange in integrin ligation, suggesting a role for thiol isomerization in integrin function. Thus Yan et al. have detected unpaired cysteines in the 3 subunit of IIb 3 (2); disruption of disulfide bonds in the 3 subunit by site-directed mutagenesis or mild proteolysis increase the affinity of IIb 3 to its ligand, fibrinogen, (3) (4) (5) (6) (7) , and introduction of disulfide bonds into integrin L 2 affected its affinity (8, 9) . We have reported that extracellular sulfhydryls participate in conformational changes triggered by interaction of the platelet integrin 2 1 with its natural ligand collagen (10). We subsequently reported that disulfide exchange is required for platelet adhesion to collagen, fibronectin and fibrinogen (11, 12) . Furthermore, involvement of disulfide exchange in adhesive receptor function is a feature specific to the integrin receptor family (12) though other receptors may contribute to this process (13) (14) (15) .
This disulfide exchange appears to be controlled by protein-disulfide isomerase activity (11, 12) , provided either by activity intrinsic to the integrin (16) , or by protein disulfide isomerase (PDI) present on the platelet surface (17) (18) (19) (20) .
The observed involvement of disulfide exchange in platelet adhesion to collagen, fibronectin and fibrinogen might be mediated by one of several pathways: a converging route, where stimulated IIb 3 contributes to adhesion to all three ligands and depends on exposure of free thiols; an integrin-specific route, where the ligand-specific integrins 2 1 , 5 1 and IIb 3 each display thiol-dependent ligation; and a more general route where disulfide exchange is involved in ligation of receptors of different families.
The human platelet expresses several collagen receptors, recently reviewed (21) (22) (23) , two of which, integrin 2 1 and the immune receptor, GPVI, are well-characterized and particularly suitable to distinguish between these possible pathways. Integrin 2 1 exerts primarily adhesive function, recruiting platelets to collagen surfaces under arterial flow conditions (24, 25) . Deficiency of 2 1 leads to bleeding dysfunction (26) (27) (28) , and its expression has been correlated with increased risk of coronary thrombosis and stroke (29) (30) (31) . We have shown that increased collagen-binding affinity correlates with disulfide re-arrangement within 2 1 on the intact platelet (10). In contrast, GPVI, recently cloned and sequenced (32, 33) , serves a key signaling role (34) , which leads to aggregation through activation of IIb 3 , which further augments platelet adhesion to collagen (35) . Deficiency in GPVI also leads to bleeding For personal use only. on October 17, 2017 . by guest www.bloodjournal.org From diathesis (36) .
Synthetic peptide ligands specific for either GPVI or 2 1 have been developed in this laboratory. These adopt a collagen-like triple-helical conformation by virtue of their high Gly-Pro-Pro (GPP) or Gly-Pro-Hyp (GPO, O = hydroxyproline) content. The GPO polymer, collagen-related peptide (CRP), is specific for GPVI and, when cross-linked, is a potent platelet activator (37) . The specific 2 1 ligand (38, 39) , GFOGER-GPP, comprises the recognition motif GFOGER from type I collagen (40) within GPP repeats at the C-and Ntermini, and it neither binds GPVI nor stimulates platelet aggregation. Both peptides support static platelet adhesion, allowing receptor-specific adhesive events to be discriminated.
The present work was designed to explore the involvement of disulfide exchange and PDI in specific receptor-ligand interactions. We studied platelet adhesion to immobilized CRP or GFOGER-GPP or monomeric type I collagen in the presence of different blockers of free thiols or inhibitors of PDI, to probe the specific competence of GPVI and 2 1 . We also measured the effect of these agents on ligation of purified 2 1 and of its recombinant Idomain. The blocking agents used were: the membrane-impermeant thiol reagents DTNB and pCMPS, the antibiotic cyclic peptide bacitracin, in both crude and purified form, and two antibodies specific for PDI. To discriminate between possible activation-dependent platelet adhesion mediated by the fibrinogen receptor IIb 3 and direct adhesion mediated by collagen receptors, adhesion studies were performed using platelets from type I Glanzmann's thrombasthenic patients, which lack IIb 3 . In addition, normal platelets were used in the presence of fibrinogen receptor antagonists, the RGD mimetic GR144053F and the IIb 3specific monoclonal antibodies 7E3 and 10E5. Our data indicate that GPVI-mediated platelet adhesion to collagen is independent of disulfide exchange, that IIb 3 is not involved in thiol dependent adhesion to collagen and that enzymatically-catalyzed disulfide exchange is a necessary process in 2 1 -mediated, but not I-domain -mediated, adhesion to collagen.
EXPERIMENTAL PROCEDURES

Materials
Washed or gel-filtered platelets were used throughout within 3h of venipuncture. Blood was obtained either from healthy volunteers who had not ingested any medications for at least 12 days prior to venipuncture, or from the apheresis clinic of the National Blood Service, Cambridge, UK. Glanzmann's type I platelets, obtained from informed donors, were from I collagen fibers, used for platelet aggregation, were a gift from Ethicon Inc., Somerville, NJ, and were dialyzed against 0.01 M acetic acid. Monomeric type I collagen used for adhesion assays was purified from calfskin, following limited pepsin digestion (41) . For aggregation studies, polymerized collagen was used. The peptides CRP: GCO(GPO) 10 GCOG, GFOGDR-GPP: GPC(GPP) 5 GFOGDR(GPP) 5 GPC, GPP10: GPC(GPP) 10 GPC and GFOGER-GPP: GPC(GPP) 5 GFOGER(GPP) 5 GPC, were synthesized by standard Fmoc chemistry. Cys residues were not blocked, allowing cross-linking to produce CRP-XL for aggregation studies using the bi-functional SPDP reagent (Sigma-Aldrich) (42) .
Human plasma fibrinogen type I, p-nitrophenyl phosphate, bovine serum albumin (BSA), PGE 1 School of Medicine, New York, N.Y. Mouse monoclonal anti-PDI, clone RL-90, (ascites fluid) was purchased from Affinity Bioreagents Inc., Golden, CO. GR144053F was a gift from Glaxo Wellcome, Stevenage, UK. Fab fragments of rabbit anti-PDI, and control Fab fragments were prepared as previously described (18, 19) . Bacitracin A, the predominant species in commercial bacitracin, was a generous gift of Dr. Leo Kesner (Department of Biochemistry, SUNY-Downstate Medical Center). The bacitracin A was purified during the purification of the insulinase inhibitor fraction from commercial bacitracin (Sigma Chemical Co., St. Louis, MO) using CM-Sepharose followed by Bio-Gel P4 chromatography as described in detail elsewhere, (Medina, 1993) . HPLC analysis of each bacitracin fraction was performed as described and identified bacitracin A as the predominant species in the sixth peak off the P4 column (43) .
Methods
Platelet adhesion to protein-or peptide-covered plastic was measured using two methods which gave very similar results. In method (a), 24-well suspension culture plates were coated with 20 µg/ml collagen, or monomeric CRP or GFOGER-GPP, in 0.01M acetic acid, for 2h at room temperature, followed by washing in PBS and blocking with 3mg/ml BSA for 1h as For personal use only. on October 17, 2017. by guest www.bloodjournal.org From described (11) . Coated surfaces, were used on the day of preparation, and not allowed to dry. 300µl of washed platelets (45) or gel-filtered platelets (10,46) were used per well at a final concentration of 2x10 7 platelets/ml in adhesion buffer (12mM NaHCO 3 , 138mM NaCl, 5.5mM glucose, 2.9mM KCl, 50mM HEPES, 2mM MgCl 2 , 1mM CaCl 2 , pH 7.3). Inhibitors, in platelet-adhesion buffer, were added to platelets 10 min before the adhesion process commenced. Monoclonal antibodies or isotype-matched ascites control were added 30 min prior to the assay. After 45 min incubation, non-adherent platelets were removed by washing with PBS, adherent platelets were stained in May-Grünwald and counted microscopically.
Protein-covered wells incubated with untreated platelets were always included as reference,
showing adhesion of 250-1000 platelets/mm 2 depending on the donor. Adhesion to BSAcovered surfaces was typically less than 1% of adhesion to blocked collagen or peptidecovered surfaces. Results were calculated as "% residual adhesion" i.e. the number of adherent platelets in the presence of the inhibitor relative to adherence to the same substratum without inhibitor (11, 12) . Each experiment was repeated at least three times.
In method (b), 96-well plates were coated with 10 µg/ml collagen, monomeric CRP or GFOGER-GPP dissolved in 0.01M acetic acid for 1h at room temperature (44) . Tris-HCl, 140mM NaCl, 2mM Mg 2+ and 0.1% BSA). Washed platelets were incubated with inhibitors for 20 min then transferred to coated wells for 1h as described (47) . After washing the adherent platelets, 150µl of lysis buffer (0.07M trisodium citrate, 0.3M citric acid, 5mM p-nitrophenol phosphate and 0.1% triton X-100, v/v) were added. After 1h, the reaction was stopped by adding 100µl 2M NaOH and the product quantitated by measuring A 405 (48) .
Results are expressed as % residual adhesion, defined above. Using this method, approximately 45% of platelets adhered to the collagen-or peptide-coated surface of the well under control conditions.
Significance of the effect of inhibitors on platelet adhesion was tested by one-way ANOVA, using mean values from at least three separate experiments, and identified using the Student-Newman-Keuls multiple comparison test. Integrin 2 1 was purified from solubilized membranes of human platelets by affinity chromatography on collagen-sepharose (40, 44) , biotinylated as described, used in solid phase For personal use only. on October 17, 2017. by guest www.bloodjournal.org From binding assay (40, 44) and detected using horseradish peroxidase-coupled streptavidin.
Purified 2 1 contained no detectable PDI, as demonstrated by Western blotting using the anti -PDI antibody RL-90 (data not shown).
Recombinant 2 I-domain was produced as a glutathione S-transferase (GST) fusion
proteinand used in solid phase binding assays as described previously (38, 44) . It was detected using a rabbit anti-GST antibody (Pharmacia Biotech, Bucks, UK). Platelet aggregation studies were performed by turbidimetric aggregometry, as described (49) .
Adhesion of either
Briefly, platelets were suspended in Tyrode's buffer (138mM NaCl, 5.6mM glucose, 1mM MgCl 2 , 0.4mM NaH 2 PO 4 , 12mM NaHCO 3 , 2.7mM KCl, 10mM HEPES, 1.5mg/ml fibrinogen, 1.5mM CaCl 2 and 0.35 % BSA) (50), which was supplemented 1.5mg/ml fibrinogen. The assay was carried out with native type I collagen fibers from bovine tendon, CRP-XL or thrombin as agonists. In the latter case fibrinogen was omitted from the platelet suspension.
RESULTS
Inhibitory effect of bacitracin on collagen-but not CRP-XL-induced platelet aggregation.
Platelet aggregation was performed with washed platelets, allowing comparison with previous reports (18, 19) . Type I collagen fibers and CRP-XL were used at the minimum concentration that caused full aggregation (0.5µg/ml and ~0.1µg/ml respectively). Pre-incubation of platelets with 3mM bacitracin was sufficient to block collagen-induced platelet aggregation completely ( Figure 1A) , whereas CRP-XL still triggered some platelet aggregation (Figure To ascertain whether bacitracin impaired the viability of platelets, or invoked its effect by proteolytic activity, aggregation tests were performed using platelets which had been preincubated with 12mM bacitracin, more than sufficient to block aggregation completely.
Platelets were then centrifuged and resuspended in buffer without bacitracin. Normal aggregation was induced by collagen fibers ( Figure 1C ) in the resuspended platelets, indicating that the inhibitory effect of bacitracin was reversible and not caused by general toxic or lytic activity. Similar data were obtained for aggregation stimulated by CRP-XL (not shown). Platelets were pre-incubated for 10 min with the indicated concentration of commercial bacitracin, then agonist was applied at the points shown by arrows, A: collagen fibers at 0.5µg/ml, and B: CRP-XL at 0.1µg/ml. In C, platelets were preincubated with or without bacitracin (12mM or control respectively) for 1h, then washed and resuspended in HEPES-Tyrode's buffer without bacitracin, then aggregation was stimulated with collagen (1µg/ml). Aggregation, measured as described in Experimental, is shown as an increase in light transmittance, a representative experiment of three.
Effect of GR144053F, bacitracin and anti-PDI on thrombasthenic platelet adhesion to collagen, CRP and GFOGER-GPP.
To provide definitive resolution of the role of IIb 3 from that of 2 1 or GPVI in disulfideexchange dependent platelet response to collagen, adhesion of Glanzmann platelets from two separate donors to surfaces coated with monomeric collagen, GFOGER-GPP or CRP was examined. GR144053F had no effect on adhesion of thrombasthenic platelets to any of the collagenous substrates ( Figure 2 ) confirming it as a specific IIb 3 inhibitor. Bacitracin A (3mM) blocked adhesion of Glanzmann's platelets to collagen by 35 and 50% and to GFOGER-GPP by 60 and 85% in platelets from the two donors, whilst having no effect on adhesion to CRP, confirming bacitracin as 2 1 -specific (Figure 2A and 2B) . The thiolexchange blocker, DTNB, used in one experiment, caused near-complete blockade of adhesion to both monomeric collagen and GFOGER-GPP, having only a slight effect on adhesion to CRP (Figure 2A ). In the second experiment ( Figure 2B ) Fab fragments of anti-PDI, previously shown to fully inhibit collagen-induced platelet aggregation (18), inhibited
Glanzmann's platelet adhesion to monomeric collagen and to GFOGER-GPP by 36% and 82% respectively. Control Fab fragments had no effect on adhesion to either substrate. Thrombasthenic platelets were incubated with GR144053F (2µM), bacitracin A (3mM), DTNB (2.5mM) or anti-PDI Fab fragments (400µg/ml) as indicated, then allowed to adhere to the indicated substrates for 1h using adhesion method (b). A single experiment performed in triplicate (Mean ± S.D.) was performed with platelets from each of two donors, A and B, Residual adhesion is expressed relative to untreated controls.
Distinguishing mediation by integrin IIb 3 from mediation by 2 1 and GPVI in disulfideexchange dependent adhesion of normal platelets
To assess the possible contribution of activated IIb 3 versus that of 2 1 in normal platelets, the effect of 6mM bacitracin and of the blocking monoclonal antibody 6F1 against 2 1 was compared with that of the blocking antibodies against IIb 3 , 10E5 and 7E3, as well as the RGD-mimetic GR144053F, using adhesion method (a). Collagen, GFOGER and CRP were used as adhesive substrates and isotype-matched mouse ascites was used as control. The results, shown in Table I , demonstrate that adhesion to collagen was 75% inhibited by 6mM
bacitracin and not at all by GR144053F, 10E5 or 7E3, indicating lack of involvement of IIb 3 in disulfide exchange-mediated adhesion to collagen. Adhesion to CRP was not inhibited by either anti-2 1 or anti-IIb 3 , nor was it inhibited by bacitracin, stressing lack of involvement of either disulfide exchange or IIb 3 in platelet interaction with the GPVI specific peptide.
Adhesion to GFOGER was not inhibited by anti -IIb 3 , but totally inhibited by both anti- 2 1 and bacitracin, indicating direct involvement of the collagen receptor 2 
Dose-dependent inhibitory effect of bacitracin on platelet adhesion to GFOGER but not CRP.
Adhesion of platelets to surfaces coated with monomeric collagen, GFOGER-GPP or CRP was tested as a function of bacitracin concentration. Platelet adhesion to CRP was not inhibited by 6mM bacitracin whereas adhesion to GFOGER-GPP was substantially inhibited at less than 3mM ( Figure 3A ). Adhesion to collagen was also inhibited, in agreement with previous data (11) .
Commercially available bacitracin may contain impurities which have non-specific effects on platelet function (52) . Therefore, as for aggregation, we determined whether exposure to bacitracin had irreversible (non-specific) effects on platelet adhesion. After pre-incubation with either 12mM or 30mM bacitracin, the platelets were centrifuged once, and resuspended in adhesion buffer. After the removal of bacitracin, residual adhesion of platelets to monomeric collagen was 119 and 76% respectively, where adhesion in the presence of these levels of bacitracin was reduced to 31% and 7% (p < .001, data not shown). Thus, platelets substantially regained their ability to adhere to monomeric collagen after incubation with high levels of bacitracin, in agreement with our previous report (11) .
In addition to the reversibility tests described above, we tested the effect of purified bacitracin A on platelet adhesion to the same coated surfaces. Again, inhibition of platelet adhesion to monomeric collagen and to GFOGER-GPP was near-complete using 3mM bacitracin A, with EC 50 about 2.5mM, whereas adhesion to CRP was not affected ( Figure 3B ). 
Effects of anti-PDI antibodies on adhesion to receptor-specific peptides.
We have reported that monoclonal anti-PDI antibody RL-90 inhibits platelet adhesion to collagen (11) , and that Fab fragments of polyclonal anti-PDI antibody inhibit collageninduced platelet aggregation (18) . We therefore tested both antibodies for their effect on platelet adhesion to CRP and to GFOGER-GPP. RL-90 inhibited platelet adhesion to the 2 1 -specific ligand, GFOGER-GPP, by more than 70%, but had no effect on adhesion to the GPVI-specific peptide CRP ( Figure 4A ). RL-90 also inhibited platelet adhesion to monomeric collagen (data not shown) as previously reported (11) . Moreover, Fab fragments of the polyclonal anti-PDI inhibited platelet adhesion to GFOGER-GPP by a similar extent, but had no effect on adhesion to CRP (Fig. 4B ). In these experiments both ascites and Ig Fab fragment controls were without effect. . Anti-PDI antibodies inhibit adhesion of platelets to GFOGER-GPP but not CRP. A: Washed platelets were incubated with 0.5% dilution of monoclonal antibody RL-90 or control ascites, as indicated, then allowed to adhere to GFOGER-GPP or CRP. Residual adhesion after 45 min was measured as described in Experimental, using adhesion method (a). Data represent mean ± S.D. of two separate experiments, each measured in duplicate. B: Platelets were incubated for 20 min with Fab fragments of either polyclonal anti-PDI or control IgG (400µg/ml), then allowed to adhere to GFOGER-GPP or CRP. Residual adhesion after 1h was measured as described in Experimental, using adhesion method (b). Data are Mean ± S.D. of three experiments, each measured in triplicate (p<0/001).
Effects of DTNB and pCMPS on adhesion to receptor-specific peptides.
DTNB, an irreversible inhibitor of disulfide exchange, blocked platelet adhesion to monomeric collagen and to GFOGER-GPP in a dose-dependent manner, inhibition being
For personal use only. on October 17, 2017. by guest www.bloodjournal.org From near-complete at 2.5-mM. Adhesion to CRP was not affected ( Figure 5A) .
To test the possibility that platelet surface proteins became disulfide-bridged directly to the immobilized peptide, two sets of experiments were performed. In the first, an analogue of GFOGER, the control peptide GFOGDR which does not recognize 2 1 (38) and the control peptide GPP10 which does not recognize GPVI (42) were used. As seen in Fig 5B, platelets did not adhere to the control peptides while they adhered well to the 2 1-specific peptide GFOGER, in agreement with previous reports (38, 42) . In a second experimental design, GFOGER-coated surfaces were pre-treated with DTNB, or with buffer control. DTNB was removed by washing and adhesion of platelets to the surface was measured in the presence of increasing concentrations of DTNB as done before. We observed that pretreatment of the peptide-covered surface with DTNB led to no loss of platelet adhesion, and the dosedependent effect of added DTNB was identical whether the surface peptide had been pretreated with DTNB or not ( Figure 5C ). .
The action of pCMPS, another irreversible blocker of thiols and inhibitor of disulfide exchange, proved to be similar to DTNB, with significant inhibition of adhesion to both monomeric collagen and GFOGER-GPP at levels of pCMPS which had no effect on adhesion to CRP ( Figure 5D ). Data for collagen are consistent with our previous report (11) . , are from three different experiments, performed in triplicate using adhesion method (b). B: Platelet adhesion to GFOGDR-GPP and to GPP10 was compared with adhesion to GFOGER, using method (b), in a single experiment repeated in triplicate (mean ± S.D.), confirming previously published data (38, 42) . C: Surfaces were coated with GFOGER, as for A, then pre-treated for 30 min with 10mM DTNB (black bars) or the vehicle for DTNB, phosphate buffer (grey bars). After washing the surfaces with phosphate buffer, platelets were added in the presence of the indicated level of DTNB, and adhesion measured as for A. D: Platelet adhesion to the three substrates was measured, as described, in the presence of increasing levels of pCMPS. Data are from three separate experiments, each performed in triplicate (Mean ± S.D.), using adhesion method (a). Where error bars are absent, they were too small to show
The role of thiols and disulfide exchange in ligation of purified 2 1 and of its recombinant I domain .
To compare the kinetics of binding of 2 1 with that of its I-domain, the adhesion of purified integrin and recombinant I-domain (which is the collagen binding region of 2 1 and the specific binding domain of GFOGER) to GFOGER-GPP-coated surfaces was examined as a function of their concentration. Adhesion was detected using an anti-2 I-domain antibody. Background adhesion (the minor component remaining in the presence of EDTA) was subtracted from that in the presence of 2mM Mg 2+ . We observed a much higher binding of intact 2 1 to GFOGER. Integrin binding became saturated at 2µg/ml, whereas I-domain binding did not yet reach saturation at 5µg/ml. In order to assess the role of disulfide exchange in direct interaction of 2 1 with its ligand, ligation of purified 2 1 (1µg/ml) to its specific ligand, GFOGER-GPP, was measured in the presence of increasing concentrations of the thiol blocker DTNB, the disulfide-exchange inhibitor bacitracin and anti-PDI RL-90. Three different experiments were performed, each in triplicate. As can be seen (Fig. 6B) , DTNB inhibits binding of 2 1 to GFOGER-GPP in a concentration-dependent manner indicating that free thiols are necessary for adhesion of the purified receptor to its ligand. However blocking disulfide exchange with bacitracin, or inhibiting PDI with RL-90 did not affect this ligation. We next tested ligation of the recombinant I-domain. In three experiments we observed that neither DTNB nor bacitracin had a significant effect on ligation (Fig. 6C) . Fig. 4 , and allowed to adhere to immobilized GFOGER-GPP as described in Experimental. Adhesion was measured using HRP-linked streptavidin, and data shown are Mean ± S.D. from three experiments, each performed in triplicate. Residual adhesion is expressed relative to untreated controls. C. Recombinant 2 I-domain was incubated with 10mM DTNB, or 30mM bacitracin (Bac), allowed to adhere to immobilized GFOGER-GPP and estimated using anti-GST as described in Experimental. Data are Mean ± S.D. from three experiments each performed in triplicate concomitantly with A. Residual adhesion is expressed relative to untreated controls.
DISCUSSION
Recently, we have suggested that disulfide exchange has a role in the affinity-modulation of the collagen receptor, integrin 2 1 (10,11), as well as of integrins IIb 3 (11, 12, 18, 20) and 5 1 (11) . Together, these studies suggested that disulfide exchange is a general requirement for outside-in signaling by integrins. However, the blood platelet expresses two different receptors for collagen: integrin 2 1 and the immunoglobulin superfamily receptor GPVI.
The activated fibrinogen receptor, integrin IIb 3 , may also mediate indirect adhesion to collagenous ligands following platelet activation (35, 44) . Therefore disulfide exchangedependent interaction with collagen could in principle be mediated by either of the collagen receptors or by the activated fibrinogen receptor. This study aimed to probe the receptor specificity of disulfide exchange and PDI in platelet adhesion to collagen. Bacitracin, an inhibitor of disulfide exchange (53, 54) , inhibits platelet aggregation triggered by collagen (12, 18, 20) . To investigate the possible involvement of disulfide-exchange in the function of GPVI, the effect of bacitracin was first examined on platelet aggregation stimulated by crosslinked CRP, which acts specifically through this receptor (42, 55) . Although bacitracin reduced platelet aggregation triggered by CRP-XL, some aggregation persisted despite the presence of bacitracin at concentrations that totally inhibited collagen-induced aggregation ( Figure 1 ). As expected, higher levels of bacitracin inhibited aggregation by CRP-XL as well as by thrombin, because the aggregation process mediated by sustained ligation of integrin IIb 3 , is itself sensitive to blockade of disulfide exchange (12) . Bacitracin was not toxic or proteolytic, since the ability of platelets to aggregate was restored by washing it from the suspension. These observations suggested greater dependence on disulfide exchange of the activation pathway stimulated by native collagen fibers, where receptors other than GPVI, such as integrin 2 1 or activated IIb 3 , may contribute.
Platelets from two Glanzmann's thrombasthenic patients, shown by flow cytometry to lack IIb 3 on their surface (M. Makris, unpublished data), allowed us to resolve direct dependence of the collagen receptor(s) on disulfide exchange from IIb 3 -mediation in disulfide exchange.
We made use of the two peptides specific to the collagen receptors and selective for them: GFOGER, the 2 I-domain recognition motif from type I collagen (40) , in a triple-helical synthetic peptide which is specific for integrin 2 1 (38, 39) and CRP, the GPVI-specific peptide (42, 55) . This also allowed resolution of the possible selectivity of disulfide exchange For personal use only. on October 17, 2017. by guest www.bloodjournal.org From in ligation of the two collagen receptors. First, the functional defect in these platelets was confirmed by their inability to aggregate when treated with a normal level of CRP-XL (not shown). We then used these Glanzmann platelets in adhesion studies, where we observed that the RGD-mimetic, GR144053F, had no effect on their adhesion to either GFOGER-GPP or CRP (Figure 2 ). Therefore adhesion of thrombasthenic platelets to GFOGER-GPP and CRP is completely independent of IIb 3 but dependent on integrin 2 1 and GPVI respectively.
Inhibition of adhesion of these platelets to GFOGER-GPP by DTNB, bacitracin or anti-PDI Fab fragments ( Figure 2) show that free thiols and PDI-mediated disulfide exchange are directly involved in the function of 2 1 . In contrast, lack of effect on adhesion to CRP ( Figure 2) shows that GPVI-mediated adhesion is independent of disulfide exchange.
To probe possible involvement of IIb 3 in thiol-mediated adhesion of normal platelets to the collagenous peptides, integrin IIb 3 was blocked using either antibodies 10E5 and 7E3 (56) or the RGD-mimetic GR144053F (37, 42) . Under these conditions, adhesion to GFOGER-GPP or CRP was not affected ( Table 1) . As expected (37, 44) , monoclonal antibody 6F1, directed at 2 1 (57), totally blocked adhesion to GFOGER-GPP and to monomeric collagen but not to CRP. Similarly, 3mM bacitracin inhibited platelet adhesion to GFOGER-GPP and to collagen, but not to CRP (Table 1 ). These data suggest that amongst those receptors mediating adhesion of the normal platelet to collagen, it is 2 1 , but not IIb 3 or GPVI, that is an important target for disulfide exchange.
Bacitracin inhibited adhesion to GFOGER-GPP in a dose-dependent manner while having no inhibitory effect on adhesion to CRP ( Figure 3A ). Adhesion to monomeric collagen, a process also essentially dependent on 2 1 , was inhibited by bacitracin, in agreement with our previous observations (11) . The effect of bacitracin is reversible, as adhesion is fully restored if it is washed away, confirmed here (not shown) and as reported previously (11) , ruling out any possible proteolytic or other toxic effect. The purified active fraction of bacitracin, bacitracin A, showed similar selectivity for 2 1 (Figure 3B ), further ruling out possible effects of impurities. Thus, it is the integrin-mediated adhesion that depends on disulfide exchange activity.
Bacitracin was recently shown to inhibit disulfide exchange-activity endogenously expressed in 3 and possibly 1 integrins (16) as well as that of PDI. Therefore the direct involvement of PDI in collagen-receptor ligation was examined by exploring the effect of two antibodies specific to this enzyme on platelet adhesion to the two peptides. Monoclonal antibody RL-90, raised against purified PDI (58) , blocks PDI activity (59) and platelet adhesion to monomeric collagen (11) . This antibody inhibited normal platelet adhesion to GFOGER-GPP but not to CRP ( Figure 4A ). Fab fragments of polyclonal anti-PDI, previously shown to inhibit agonistinduced platelet aggregation (18) , also inhibited adhesion to GFOGER-GPP and not to CRP ( Figure 4B) . Thus, notwithstanding possible involvement of endogenous disulfide exchange activity in 2 1 , these data suggest that PDI is also involved in 2 1 -mediated adhesion.
Direct blocking of free sulfhydryls inhibits platelet adhesion to collagen in a manner very similar to that of bacitracin or anti-PDI (11) . Here two thiol blockers, DTNB and pCMPS inhibited adhesion to GFOGER-GPP in a concentration-dependent manner while adhesion to CRP was not affected (Figures 5A and 5B) . The doses used for these reagents, as for bacitracin, were consistent with previous reports (11, 12, 20, 60) . To control for the possibility that platelets formed disulfide bonds non-specifically with the cysteine-containing peptides, GFOGER-GPP-coated surfaces were derivatized with supramaximal levels of DTNB. This affected neither platelet adhesion after washing the surfaces free of soluble DTNB nor the inhibitory properties of DTNB on platelet adhesion ( Fig 5C) . Two lines of evidence further support specificity of free thiols for 2 1 -mediated adhesion: a) in confirmation of previous reports (38, 42) , non-specific contact with homologous cysteine-containing peptides, GFOGDR-GPP and GPP10, to which neither 2 1 nor GPVI will bind (38, 42) , did not support platelet adhesion (Fig.5B) , and b) specific platelet adhesion, mediated by GpVI, to CRP was completely insensitive to the presence of DTNB ( Fig.2A) . Thus free thiols are necessary specifically for 2 1 -mediated adhesion.
Bacitracin-induced inhibition of adhesion of lymphoid cells to collagen has been reported by
Mou et al. (60) . However, these authors suggested that since both their anti-PDI and DTNB had little effect on cell adhesion to collagen, the action of bacitracin was non-specific. Our results differ, since DTNB had a very marked inhibitory action on platelet adhesion (Figures   2A, 5A) , as did anti-PDI ( Figures 2B, 4 ). Further, we obtained similar data using a second thiol reagent, pCMPS ( Figure 5D ). Possibly the antibody and Fab fragments used in our study were more specific for the catalytic activity of PDI than that used by Mou et al. (60) . It may also be, however, that the regulation of 2 1 in lymphocytes differs from that in platelets.
Up to this point this study shows that disulfide exchange is a necessary step in adhesion mediated by integrin 2 1 and implies specific involvement of surface-expressed PDI activity in this process. It still does not address possible involvement of endogenous disulfide (16) . It also does not exclude possible involvement of other integrin-associated proteins in this thiol-dependent process. We therefore used purified 2 1 and its I-domain in adhesion studies.
To compare the kinetics of binding of purified intact 2 1 with that of its isolated I-domain to GFOGER, which is the collagen binding region of 2 1 specifically recognized by the Idomain (38), we exposed GFOGER-coated surfaces to increasing levels of these proteins, estimating adhesion of each using the same monoclonal antibody. These experiments showed that on a molar basis the apparent affinity of intact 2 1 was almost two orders of magnitude higher than that of the free 2 I-domain, the structure within 2 1 which binds type I collagen.
This suggests that components of the integrin other than the I-domain are responsible for the regulation of its affinity.
We therefore probed ligation of 2 1 to GFOGER-GPP in the presence of DTNB, bacitracin and RL-90. 2 1 , purified from normal human platelets and free of PDI, was increasingly inhibited from binding to GFOGER-GPP by increasing concentrations of DTNB ( Figure 6B ).
Thus, free thiols are necessary for direct interaction of 2 1 with its ligand. Presentation of free thiols by a purified integrin has been previously demonstrated for IIb 3 (2, 61) . This receptor was also shown to carry endogenous disulfide exchange activity, as does v 3 (16) .
Thus, endogenous disulfide exchange activity of 2 1 could explain thiol involvement in the absence of PDI. However, inhibiting disulfide exchange activity with bacitracin had no effect on the direct ligation of 2 1 (Figure 6B ). The reasons for this difference between the integrins will have to be further investigated. As expected, blocking PDI activity with RL-90 had no effect on ligation of purified 2 1 ( Figure 6B ).
We further probed thiol-dependence of the interaction of recombinant I domain with immobilized GFOGER. We found that ligation of the I-domain was independent of free thiols as well as of disulfide exchange ( Figure 6C ). This observation agrees with the previous report showing that no cysteine in the I-domain plays a role in its ligation (62) . Yet our data allow us to define integrin 2 1 as the site of disulfide exchange. We therefore suggest that the initial interaction of the I-domain in 2 1 with its ligand causes allosteric conformational changes that expose free thiols in another domain on 2 1 needed for sustained ligation of 2 1 . We have recently demonstrated such sequence of processes, whereby initial integrin ligation is thiol-independent, followed by thiol-dependence for sustained ligation in IIb 3 (12) . This sequence is also supported by our previous report showing that following adhesion For personal use only. on October 17, 2017. by guest www.bloodjournal.org From to collagen, integrin 2 1 undergoes affinity modulation involving disulfide-bond rearrangement (35) . Further, a regulatory mechanism whereby ligation of the I-domain in 2 1 involves regulation through conformational changes in the 1 subunit has been demonstrated (63) , implicating the EGF repeats of 1 (63) . Recently, it was demonstrated that a point mutation (C560R) in the cysteine-rich domain of the 3 subunit irreversibly activates IIb 3 (7) . It was also reported that while yet another point mutation in the cysteine-rich domain, C598Y, also locks IIb 3 in the active conformation, two mutations in the I-like domain of 3 , C177A and C273A, had no such effect (6) . Further, free sulfhydryls have been located within the 3 subunit (64), providing a possible site of disulfide exchange. The recent crystal structure of the extracellular domains of v 3 suggests that the cysteine-rich stem of the 3 subunit is the site of a conformational change which may be associated with the activation process (65) . Together, these data are consistent with the concept that disulfide exchange is crucial for the sustained binding of integrins to their ligands, is common to different platelet integrins and is independent of the presence of the I-domain, which is found in the 2 but not in IIb subunit. The two integrins are structurally similar in many other respects. By contrast, ligation of non-integrins is independent of disulfide exchange. This was demonstrated here with respect to GPVI, and previously with respect to GPIb-IX-V (12).
How then, can PDI regulate the affinity of 2 1 ? We propose that 2 1 exists in two conformations, determined by the state of disulfide bridging (presumably within the 1subunit) (2, 61, 63) where the equilibrium between the two forms is enzymatically-catalyzed by disulfide exchange activity. It would therefore be necessary that the active conformation can be stabilized by ligand binding, and that a mechanism exists for this information to be relayed allosterically from the I-domain, which is the ligand-binding domain in 2 1 , to the rest of the integrin. Indeed such a mechanism has recently been proposed, based on the conformational changes observed within the 2 I-domain upon binding a GFOGER-containing peptide, determined at the level of their crystal structures (39). Table 1 . Involvement of integrins IIb 3 and 2 1 and of bacitracin in adhesion to collagen and to receptor-specific peptides.
Platelet adhesion (% of adhesion in the presence of ascites control) Collagen GFOGER CRP (mean ± SE) (mean ± SE) (mean ± SE) Anti- IIb Bacitracin (6mM) 25 ± 5 (n=13) 12 ± 8 (n=4) 77 ± 11 (n=3) Adhesion in the presence of non-immune ascites, diluted 1:100, had no effect on adhesion to any of the substrates. Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
